Repligen Corporation (NASDAQ:RGEN) Shares Sold by Zevenbergen Capital Investments LLC

Key Points

• Zevenbergen Capital Investments LLC reduced its stake in Repligen Corporation by 22.3%, selling 25,160 shares and currently holding 87,587 shares worth $11,145,000.
• Barclays and Stephens have given overweight ratings on Repligen, with target prices of $150 and $160 respectively, while the stock currently has an average price target of $169.45.
• Repligen reported a quarterly earnings miss, with an EPS of $0.37, below the expected $0.40, although its revenue increased by 14.8% year-over-year to $182.37 million.

Zevenbergen Capital Investments LLC lessened its holdings in Repligen Corporation (NASDAQ:RGEN - Free Report) by 22.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 87,587 shares of the biotechnology company's stock after selling 25,160 shares during the quarter. Zevenbergen Capital Investments LLC owned approximately 0.16% of Repligen worth $11,145,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of RGEN. KBC Group NV grew its holdings in shares of Repligen by 14.9% during the first quarter. KBC Group NV now owns 2,544 shares of the biotechnology company's stock worth $324,000 after purchasing an additional 329 shares during the last quarter. Harvest Fund Management Co. Ltd purchased a new position in shares of Repligen during the first quarter worth about $132,000. GAMMA Investing LLC grew its holdings in shares of Repligen by 40.1% during the first quarter. GAMMA Investing LLC now owns 958 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 274 shares during the last quarter. XTX Topco Ltd grew its holdings in shares of Repligen by 34.2% during the first quarter. XTX Topco Ltd now owns 12,935 shares of the biotechnology company's stock worth $1,646,000 after purchasing an additional 3,295 shares during the last quarter. Finally, TD Asset Management Inc grew its holdings in shares of Repligen by 10.9% during the first quarter. TD Asset Management Inc now owns 51,172 shares of the biotechnology company's stock worth $6,511,000 after purchasing an additional 5,014 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Repligen Price Performance

Shares of RGEN stock traded down $1.54 during midday trading on Thursday, reaching $125.61. 341,034 shares of the company traded hands, compared to its average volume of 781,591. The firm's 50 day simple moving average is $122.58 and its two-hundred day simple moving average is $133.62. Repligen Corporation has a 1-year low of $102.96 and a 1-year high of $182.52. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. The firm has a market cap of $7.07 billion, a PE ratio of -502.42, a price-to-earnings-growth ratio of 2.23 and a beta of 1.05.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%. The company had revenue of $182.37 million for the quarter, compared to analyst estimates of $174.62 million. During the same quarter in the prior year, the firm earned $0.40 earnings per share. The company's revenue for the quarter was up 14.8% on a year-over-year basis. On average, equities research analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on RGEN. JPMorgan Chase & Co. lowered their price target on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday, April 29th. HC Wainwright reissued a "buy" rating and set a $180.00 price target on shares of Repligen in a report on Monday, May 5th. Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Royal Bank Of Canada raised their price target on Repligen from $193.00 to $204.00 and gave the stock an "outperform" rating in a report on Wednesday, July 30th. Finally, Wells Fargo & Company lowered their price objective on Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a report on Wednesday, July 30th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $169.45.

Insider Activity

In related news, Director Martin D. Madaus acquired 1,800 shares of the business's stock in a transaction that occurred on Friday, August 8th. The stock was purchased at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the transaction, the director directly owned 1,800 shares of the company's stock, valued at approximately $201,834. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.